Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

5322 ARTÍCULOS , VIENDO DEL 1831 AL 1845

Role of Bmal1 and Gut Microbiota in Alzheimer's Disease and Parkinson's Disease Pathophysiology: The Probable Effect of Melatonin on Their Association

Khezri MR, Esmaeili A, Ghasemnejad-Berenji M.

ACS Chem Neurosci. 2023 Nov 1;14(21):3883-3893. doi: 10.1021/acschemneuro.3c00418. Epub 2023 Oct 12.

Metabolic Basis of Circadian Dysfunction in Parkinson's Disease

Rathor P, Ch R.

Biology (Basel). 2023 Sep 28;12(10):1294. doi: 10.3390/biology12101294.

Peptide-based approaches to directly target alpha-synuclein in Parkinson's disease

Allen SG, Meade RM, White Stenner LL, Mason JM.

Mol Neurodegener. 2023 Nov 9;18(1):80. doi: 10.1186/s13024-023-00675-8.

Modulating Stress Proteins in Response to Therapeutic Interventions for Parkinson's Disease

Silvestro S, Raffaele I, Mazzon E.

Int J Mol Sci. 2023 Nov 12;24(22):16233. doi: 10.3390/ijms242216233.

Cell Therapy for Parkinson's Disease

Shastry S, Hu J, Ying M, Mao X.

Pharmaceutics. 2023 Nov 22;15(12):2656. doi: 10.3390/pharmaceutics15122656.

Gene Therapy for Dopamine Dyshomeostasis: From Parkinson's to Primary Neurotransmitter Diseases

Ng J, Barral S, Waddington SN, Kurian MA.

Mov Disord. 2023 Jun;38(6):924-936. doi: 10.1002/mds.29416. Epub 2023 May 5.

Pathological and Therapeutic Advances in Parkinson's Disease: Mitochondria in the Interplay

Naren P, Cholkar A, Kamble S, Khan SS, Srivastava S, Madan J, Mehra N, Tiwari V, Singh SB, Khatri DK.

J Alzheimers Dis. 2023;94(s1):S399-S428. doi: 10.3233/JAD-220682.

Advances in the Therapeutic Use of Non-Ergot Dopamine Agonists in the Treatment of Motor and Non-Motor Symptoms of Parkinson's Disease

Jing XZ, Yang HJ, Taximaimaiti R, Wang XP.

Curr Neuropharmacol. 2023;21(5):1224-1240. doi: 10.2174/1570159X20666220915091022.

SARS-COV-2 infection and Parkinson's disease: Possible links and perspectives

Al-Kuraishy HM, Al-Gareeb AI, Kaushik A, Kujawska M, Ahmed EA, Batiha GE.

J Neurosci Res. 2023 Jun;101(6):952-975. doi: 10.1002/jnr.25171. Epub 2023 Jan 30.

Pros and cons for statins use and risk of Parkinson's disease: An updated perspective

Al-Kuraishy HM, Al-Gareeb AI, Alexiou A, Papadakis M, Alsayegh AA, Almohmadi NH, Saad HM, Batiha GE.

Pharmacol Res Perspect. 2023 Apr;11(2):e01063. doi: 10.1002/prp2.1063.

Novel druggable mechanism of Parkinson's disease: Potential therapeutics and underlying pathogenesis based on ferroptosis

Jiang X, Wu K, Ye XY, Xie T, Zhang P, Blass BE, Bai R.

Med Res Rev. 2023 Jul;43(4):872-896. doi: 10.1002/med.21939. Epub 2023 Mar 16.

Neuroprotective Effects of Lactoferrin in Alzheimer's and Parkinson's Diseases: A Narrative Review

Yong SJ, Veerakumarasivam A, Lim WL, Chew J.

ACS Chem Neurosci. 2023 Mar 30. doi: 10.1021/acschemneuro.2c00679. Online ahead of print.

PARK7/DJ-1 in microglia: implications in Parkinson's disease and relevance as a therapeutic target

Lind-Holm Mogensen F, Scafidi A, Poli A, Michelucci A.

J Neuroinflammation. 2023 Apr 18;20(1):95. doi: 10.1186/s12974-023-02776-z.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias